Cargando…

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms

Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD) NEN of different origin (57 pancreatic NENs (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daskalakis, Kosmas, Tsoli, Marina, Angelousi, Anna, Kassi, Evanthia, Alexandraki, Krystallenia I, Kolomodi, Denise, Kaltsas, Gregory, Koumarianou, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528409/ https://www.ncbi.nlm.nih.gov/pubmed/31026812 http://dx.doi.org/10.1530/EC-19-0134

Ejemplares similares

The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
por: Tsoli, Marina, et al.
Publicado: (2020)

Increased autophagy/mitophagy levels in primary tumours of patients with pancreatic neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2020)

Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review
por: Koumarianou, Anna, et al.
Publicado: (2020)

Current best practice in the management of neuroendocrine tumors
por: Tsoli, Marina, et al.
Publicado: (2018)

Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature
por: Tsoukalas, Nikolaos, et al.
Publicado: (2017)

Heterogeneity of Small Intestinal Neuroendocrine Tumors Metastasis: Biologic Patterns of a Series with Virchow’s Node Involvement
por: Wedin, Maria, et al.
Publicado: (2022)

Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Aktypis, Charalampos, et al.
Publicado: (2021)

Currently available treatment options for neuroendocrine liver metastases
por: Machairas, Nikolaos, et al.
Publicado: (2021)

Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2018)

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Alexandraki, Krystallenia I., et al.
Publicado: (2017)

Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis
por: Tsoli, Marina, et al.
Publicado: (2020)

Malignant Pheochromocytomas/Paragangliomas and Ectopic Hormonal Secretion: A Case Series and Review of the Literature
por: Angelousi, Anna, et al.
Publicado: (2019)

IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms
por: Alexandraki, Krystallenia I., et al.
Publicado: (2017)

Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Koumarianou, Anna, et al.
Publicado: (2020)

A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors
por: Tsoli, Marina, et al.
Publicado: (2021)

Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis
por: Tsolakis, Apostolos V, et al.
Publicado: (2019)

The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms
por: Angelousi, Anna, et al.
Publicado: (2021)

Atypical manifestation of parathyroid carcinoma with late-onset distant metastases
por: Tsoli, Marina, et al.
Publicado: (2017)

Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues
por: Alexandraki, Krystallenia I., et al.
Publicado: (2019)

Clinical Utility of (18)F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis
por: Alevroudis, Emmanouil, et al.
Publicado: (2021)

Transcriptomics, Epigenetics, and Metabolomics of Primary Aldosteronism
por: Spyroglou, Ariadni, et al.
Publicado: (2021)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Association of lymph node metastases, grade and extent of mesenteric lymph node dissection in locoregional small intestinal neuroendocrine tumors with recurrence‐free survival
por: Daskalakis, Kosmas, et al.
Publicado: (2022)

Plasma Polyamines as an Additional to Imaging Biomarker in MEN1 Patients With Duodenopancreatic Neuroendocrine Tumors
por: Kassi, Eva, et al.
Publicado: (2021)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN
por: Alexandraki, Krystallenia I., et al.
Publicado: (2020)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis
por: Alexandraki, Krystallenia I., et al.
Publicado: (2023)

Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience
por: Yavropoulou, Maria P., et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
por: Fazio, Nicola, et al.
Publicado: (2021)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
por: Kurita, Yusuke, et al.
Publicado: (2022)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oqhr5hp65ajrmbp1al5jbj3u3v